Long‐term therapy‐free remission in a patient with platelet‐derived growth factor receptor beta‐rearranged myeloproliferative neoplasm

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

“…Previous studies based on less sensitive approaches indicated that the presence of CTPC in PB and/or their number, are both associated with (i) an increased risk of transformation of MGUS to MM 20 , 23 and (ii) the outcome of SMM and MM, when assessed both at diagnosis 22 , 29 , 47 , 48 , 53 and after therapy 21 , 31 – 33 . Despite the still relatively limited number of patients investigated per diagnostic category and the short median follow-up, our results confirm and extend on these findings.…”

“…Despite BM is the most frequently involved tissue in PCN 9 , 14 , 15 , and a close interaction with the BM microenvironment is required for long-term persistence of normal plasma cells (NPC) and TPC 16 – 18 , previous studies have recurrently shown involvement of peripheral blood (PB) in a substantial fraction of patients 15 , 19 – 24 . However, the frequency of PB involvement depends on the sensitivity of the methods used and the specific diagnostic subtype of PCN 15 , 19 – 23 . Thus, PB involvement by circulating TPC (CTPC) increases from MGUS -19 to 37%- to MM -50 to 75%- 19 , 24 – 26 , and PCL (100%) 8 , 27 , depending on whether immunocytochemistry or conventional 4–8-color flow cytometry are used, respectively.…”

Molecular monitoring of patients with ETV6‐PDGFRB rearrangement: Implications for therapeutic adaptation

“…Three patients discontinued their treatment, one of who remained treatment‐free after allogeneic bone marrow transplantation. More recently, Cerrano et al () reported one case of successful IM discontinuation in a paediatric patient, but without data regarding the exact level and duration of “complete” molecular remission prior to treatment discontinuation. Yet, as is commonly accepted in CML (Mahon, ), duration and depth of the molecular response prior to IM discontinuation might be predictors of success.…”